ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2574

Differences in SARS-CoV-2 Antigen Persistence in Individuals with Systemic Autoimmune Rheumatic Diseases Compared to the General Population
Abstract Number: 2575

Influenza and COVID-19 Vaccination Uptake Among Women with Systemic Rheumatic Diseases in New York City Assessed Between 2022 and 2024
Abstract Number: 2576

Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) Study: Anti-inflammatory cytokine signals related to decreased arthritis disease activity over time
Abstract Number: 2577

Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
Abstract Number: 2578

Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-Acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases
Abstract Number: 2579

Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease
Abstract Number: 2580

Estrogen Modulates Neutrophil Biology: Implications for Autoimmunity
Abstract Number: 2581

From Skin to Kidney: Neutrophil-Mediated Crosstalk Links Cutaneous Injury to Renal Inflammation and Vascular Remodeling in Lupus
Abstract Number: 2582

Inflammatory Cell Death and Impaired Efferocytosis Drive Monocyte and Macrophage Dysfunction in VEXAS Syndrome.
Abstract Number: 2583

CCL20+ monocytes expanded by HLA-B*27 fuel Th17 generation in Axial Spondyloarthritis
Abstract Number: 2584

Spatially Resolved Transcriptomics Reveal Macrophage Heterogeneity in Giant Cell Arteritis
Abstract Number: 2585

The effect of prophylactic colchicine use on gene expression in gout
Abstract Number: 2586

Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally
Abstract Number: 2587

Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
Abstract Number: 2588

Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].